Paysign is an industry growth leader with a durable moat and strong balance-sheet quality, but an overbought RSI and a thin remaining upside margin suggest much of the near-term opportunity is already reflected in the price.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Moat And Strong Returns Quality↑Improving
- Thin Remaining Upside Margin→Stable
- +2 more pillars — see the Why tab for full reasoning
Paysign, Inc. (PAYS) Stock Analysis
Technology · Software - Infrastructure
Hold if already holding. Not a fresh buy at $12.84, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.2% away).
Paysign is a vertically integrated provider of prepaid card products and payment processing services for corporate, consumer, and government customers, marketed under the Paysign brand, spanning corporate incentives, pharmaceutical patient affordability, plasma donor... Read more
Hold if already holding. Not a fresh buy at $12.84, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.2% away). Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.24, quality 7.5/10, growth 10.0/10). | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 6.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news boost analyst 0.70, earnings proximity 90d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Paysign, Inc.
About Paysign, Inc.
Paysign managed approximately 670 card programs serving 8.4 million cardholders as of December 31, 2025, spanning corporate incentive, pharmaceutical patient affordability, plasma donor compensation, and general purpose reloadable prepaid card programs. The company's Paysign Plasma Donor Compensation Prepaid Card serves approximately 48% of plasma collection centers in the United States and Puerto Rico, a niche the company entered in 2011, while its Apherion software platform serves blood and plasma collection organizations with donor management and compensation optimization tools.
Paysign earns revenue from fees generated across the prepaid card lifecycle, including cardholder fees, interchange, card program management fees, transaction claims processing fees, breakage, and settlement income, since the company does not hold a banking license and issues cards only through relationships with sponsoring bank partners. Pharmaceutical patient affordability programs pay all or a portion of a patient's out-of-pocket prescription costs on behalf of sponsoring pharmaceutical manufacturers, processed either through pharmacy transactional networks or Paysign's own internal medical-claims adjudication platform, which the company says delivers faster payments to healthcare providers than competing products. Apherion, Paysign's life science technology offering, generates revenue from licensing, hosting, and consulting fees rather than card transactions.
Show full overview
Paysign's own disclosures state the company has no major customers and is not reliant on any individual card program, a genuinely diversified base across roughly 670 programs. The more material dependency the 10-K flags is structural rather than customer-specific: because Paysign lacks its own banking license, its ability to issue open-loop cards depends entirely on relationships with card-issuing bank partners, and a portion of its revenue is tied to interchange rates set by card networks that have declined in the past following Dodd-Frank rulemaking and could decline further under future legislation.
See also: Technology · Software - Infrastructure
From Paysign, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-08-13Recent Developments — Paysign, Inc.
Latest news
- NEWS Prospect Capital Corporation Common Stock Pays Out $18 Million in Dividends Today - 24/7 Wall St. — 24/7 Wall St. neutral
- NEWS Paysign (NASDAQ:PAYS) Hits New 12-Month High - Time to Buy? - MarketBeat — MarketBeat positive
- NEWS Paysign (PAYS) to Announce Earnings on Wednesday - MarketBeat — MarketBeat positive
- NEWS PAYS|Paysign Inc|Price:9.110|Chg%:+0.220 - TradingKey — TradingKey neutral
- NEWS Want $10,000 a Year on $100K? This Preferred-Stock Fund Pays It Monthly - 24/7 Wall St. — 24/7 Wall St. neutral
Generated 2026-08-14T11:47:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $12.84, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.2% away). Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.24, quality 7.5/10, growth 10.0/10). | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Target $14.80 (+15.3%), stop $11.97 (−7.3%), A.R:R -0.8:1. Score 6.5/10, moderate confidence.
Take-profit target: $14.80 (-11.4% upside). Target $14.80 (+15.3%), stop $11.97 (−7.3%), A.R:R -0.8:1. Stop-loss: $11.97.
Analyst target reached - limited upside remaining; Near 52-week high (0.2% away); Euphoria warning: extreme positivity (+1.00) + overbought RSI 94.
Paysign, Inc. trades at a P/E of 49.2 (forward 21.2). TrendMatrix value score: 4.9/10. Verdict: Hold.
11 analysts cover PAYS with a consensus score of 4.3/5. Average price target: $13.
What does Paysign, Inc. do?Paysign is a vertically integrated provider of prepaid card products and payment processing services for corporate,...
Paysign is a vertically integrated provider of prepaid card products and payment processing services for corporate, consumer, and government customers, marketed under the Paysign brand, spanning corporate incentives, pharmaceutical patient affordability, plasma donor compensation, and general purpose reloadable cards. The company also offers Apherion, a cloud-based life science technology platform for blood and plasma collection organizations. As of December 31, 2025, Paysign managed approximately 670 card programs with 8.4 million cardholders and served approximately 48% of plasma collection